The open house process for concluding non-exclusive discount agreements for the active ingredients

- Botulinum toxin type A, ATC M03AX21, procedure 2019 / S 247- 608478,

- Enoxaparin, ATC B01AB05, procedure 2019 / S 093-224191,

- Infliximab, ATC L04AB02, procedure 2019 / S 155- 381989,

- Leuprorelin, ATC L02AE02, procedure 2019 / S 247- 608474,

- Paliperidone, ATC N05AX13, procedure 2019 / S 027 - 059520 and 2019 / S074- 174731.

Will be canceled with effect from January 31, 2021 and will be republished shortly on February 1, 2021.

This is not an open procedure, but a so-called open house model.

The procedures mentioned will be canceled with effect from January 31, 2021. It is no longer possible to conclude new contracts on the basis of these procedures. All existing contracts were terminated on January 31, 2021. A new open house procedure for the active ingredients mentioned will be published shortly.